These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 28579852)

  • 21. Emerging therapeutic options for myelofibrosis: a Canadian perspective.
    Gupta V; Foltz L; Sirhan S; Busque L; Turner AR
    Am J Blood Res; 2012; 2(3):170-86. PubMed ID: 23119228
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clarifying the use of ruxolitinib in patients with myelofibrosis.
    Kremyanskaya M; Atallah EL; Hoffman R; Mascarenhas JO
    Oncology (Williston Park); 2013 Jul; 27(7):706-14. PubMed ID: 23977767
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of myelofibrosis: JAK inhibition and beyond.
    Stahl M; Zeidan AM
    Expert Rev Hematol; 2017 May; 10(5):459-477. PubMed ID: 28395559
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Use of Allogeneic Hematopoietic Stem Cell Transplantation in Primary Myelofibrosis.
    Wolfe HR; Horwitz ME; Rein LAM
    J Pers Med; 2022 Apr; 12(4):. PubMed ID: 35455686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New strategies in myelofibrosis: the evolving paradigm of disease pathogenesis, prognostication and treatment.
    Palandri F; Auteri G; Baccarani M
    Hematol Oncol; 2017 Jun; 35(2):145-150. PubMed ID: 27510853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of Myelofibrosis: A Moving Target.
    Cerquozzi S; Farhadfar N; Tefferi A
    Cancer J; 2016; 22(1):51-61. PubMed ID: 26841017
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis.
    Ho PJ; Bajel A; Burbury K; Dunlop L; Durrant S; Forsyth C; Perkins AC; Ross DM
    Intern Med J; 2017 Mar; 47(3):262-268. PubMed ID: 28260257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Momelotinib for the treatment of myelofibrosis with anemia.
    Tremblay D; Mesa R
    Future Oncol; 2022 Jun; 18(20):2559-2571. PubMed ID: 35603634
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and laboratory features of myelofibrosis and limitations of current therapies.
    Gregory SA; Mesa RA; Hoffman R; Shammo JM
    Clin Adv Hematol Oncol; 2011 Sep; 9(9 Suppl 22):1-16. PubMed ID: 22362131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myelofibrosis: an update on drug therapy in 2016.
    Bose P; Verstovsek S
    Expert Opin Pharmacother; 2016 Dec; 17(18):2375-2389. PubMed ID: 27774820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan.
    Chen YY; Huang CE; Lee KD; Chen CC
    Hematology; 2016 Jan; 21(1):3-9. PubMed ID: 26214121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy.
    Pemmaraju N; Bose P; Rampal R; Gerds AT; Fleischman A; Verstovsek S
    Leuk Lymphoma; 2023 Jun; 64(6):1063-1081. PubMed ID: 37081809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib.
    Saha C; Harrison C
    Expert Rev Hematol; 2022 Jul; 15(7):583-595. PubMed ID: 35787092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The evolving treatment paradigm in myelofibrosis.
    Mesa RA
    Leuk Lymphoma; 2013 Feb; 54(2):242-51. PubMed ID: 22793267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.
    Griesshammer M; Sadjadian P
    Expert Opin Pharmacother; 2017 Dec; 18(18):1929-1938. PubMed ID: 29134817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myelofibrosis: an update on current pharmacotherapy and future directions.
    Cervantes F; Martinez-Trillos A
    Expert Opin Pharmacother; 2013 May; 14(7):873-84. PubMed ID: 23514013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors.
    Gupta V; Hari P; Hoffman R
    Blood; 2012 Aug; 120(7):1367-79. PubMed ID: 22700718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitors.
    Fauble V; Leis J; Mesa RA
    Leuk Suppl; 2012 May; 1(Suppl 1):S2-7. PubMed ID: 27175229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of Myelofibrosis: from Diagnosis to New Target Therapies.
    Iurlo A; Cattaneo D; Bucelli C
    Curr Treat Options Oncol; 2020 Apr; 21(6):46. PubMed ID: 32350623
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myelofibrosis: challenges for preclinical models and emerging therapeutic targets.
    Morsia E; Gangat N
    Expert Opin Ther Targets; 2021 Mar; 25(3):211-222. PubMed ID: 33844952
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.